Increased access to Mavenclad (cladribine tablets) for Multiple Sclerosis patients in Response to the COVID-19 Pandemic
Increased access to Mavenclad (cladribine tablets) for Multiple Sclerosis patients in Response to the COVID-19 Pandemic NHS England responds to the COVID-19 pandemic by simplifying eligibility requirements for patients with highly active relapsing MS starting cladribine tabletsAmends made to Blueteq form suspen...
Source: pharmiweb.com